Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vanda Pharmaceuticals's change in inventory for the quarter that ended in Mar. 2026 was $0.3 Mil. It means Vanda Pharmaceuticals's inventory
declined by $0.3 Mil
from Dec. 2025 to Mar. 2026 .
Vanda Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2025 was $-3.5 Mil. It means Vanda Pharmaceuticals's inventory
increased by $3.5 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Vanda Pharmaceuticals's Days Inventory for the quarter that ended in Mar. 2026 was 51.29.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Vanda Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2026 was 1.78.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Vanda Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.03.
Vanda Pharmaceuticals (NAS:VNDA) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Vanda Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Vanda Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanda Pharmaceuticals Change In Inventory Related Terms
Vanda Pharmaceuticals Change In Inventory Historical Data
* Premium members only.
The historical data trend for Vanda Pharmaceuticals's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanda Pharmaceuticals Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of $-1.3 Mil mean?
Vanda Pharmaceuticals (VNDA) has a Change In Inventory of $-1.3 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Vanda Pharmaceuticals and its competitors.
Is Vanda Pharmaceuticals' Change In Inventory too high?
Vanda Pharmaceuticals' current Change In Inventory is $-1.3 Mil. Overall, Vanda Pharmaceuticals has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Change In Inventory compare to LYEL and ZNTL?
Vanda Pharmaceuticals' Change In Inventory of $-1.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Vanda Pharmaceuticals and its competitors. Vanda Pharmaceuticals's current Change In Inventory is $-1.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (VNDA) is currently considered Fairly Valued. The stock's GF Value™ is $5.60, compared to a current price of $5.16 — trading 7.9% below its estimated fair value. The current Change In Inventory is $-1.3 Mil. Vanda Pharmaceuticals' overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Vanda Pharmaceuticals (VNDA), the current Change In Inventory is $-1.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanda Pharmaceuticals (VNDA) Overvalued in 2026?
Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be undervalued.
The current stock price of $5.16 is trading 7.9% below its estimated GF Value™ of $5.60.
GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.
Key valuation signals for VNDA:
Change In Inventory: $-1.3 Mil
GF Value™: $5.60 vs. price of $5.16 (7.9% below fair value)
No single metric tells the full story. See the VNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
75GF Score
Get the complete analysis for VNDA
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VNDA has been successfully added to your 
